January 8 opens with the icy moon Europa and its shadow transiting the disk of Jupiter. The two move across the disk from east to west until the shadow disappears from the eastern limb by 2:30 A.M.

Adoration of the Shepherds by Dutch painter Matthias Stom, c. 1650 Credit: Public Domain Early critics of Christianity noticed striking parallels between Danaë’s story of the birth of Perseus and the ...

Spatial proteomics enables scientists to investigate protein organization at the subcellular, cellular, and tissue levels, including in pathological contexts. Using technologies that help researchers ...

What’s going on here? Perseus Mining has secured the green light for its first underground gold mine in Ivory Coast, laying the groundwork for a bigger production boost and an extended lifespan for ...

Perseus Proteomics Inc. (4882.TO) Japan Half-Year Ended September 30 PARENT 2025 2024 Revenue Y60.00 mln Y59.00 mln Operating Profit (Y399.00 mln) (Y414.00 mln) Pretax Profit (Y345.00 mln) (Y427.00 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A rapidly growing defense tech ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...

Spatial proteomics represents a revolutionary frontier in molecular biology, enabling researchers to explore protein expression while preserving the critical spatial context of tissue architecture.

Perseus Mining moved to lock up a cornerstone West African gold growth option by tabling a binding, board-supported offer for Predictive Discovery, leapfrogging Robex Resources’ earlier agreement. The ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

Perseus Proteomics, Inc. ( (JP:4882)) has shared an announcement. Perseus Proteomics, Inc. has announced an extension of the Phase I/II clinical trial period for its anti-transferrin receptor 1 ...